Title(s):
Associate Professor of Oncology
Assistant Professor of Urology
Assistant Professor of Urology
Co-Director Prostate Cancer Multi-Disciplinary Clinic
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Bladder Cancer, Clinical Trials, General Internal Medicine, Immunotherapy, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer
Education and Experience
Training
- University of Colorado School of Medicine (Denver CO)/ (1997)
Residencies
- The Johns Hopkins Hospital (Baltimore MD)/ Medicine (1999)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Oncology Center (2002)
Certifications
- Medical Oncology, American Board of Internal Medicine (2004)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-502-7523
Appointment Phone: 410-955-8964
Fax: 443-287-4653
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Prostate Cancer Multidisciplinary Clinic
- Sidney Kimmel Comprehensive Cancer Center
Bio
Physician Title
Co-Director Prostate Cancer Multi-Disciplinary Clinic
Expertise
- Bladder Cancer
- Clinical Trials
- General Internal Medicine
- Immunotherapy
- Kidney Cancer
- Medical Oncology
- Prostate Cancer
- Testicular Cancer
Research
Research and Publications
Research Summary
To date, clinical trials of immunotherapy in patients with solid tumors have been somewhat disappointing, with response rates less than would be predicted by standard transplantable models. It seems increasingly unlikely that immunotherapy alone will prove sufficient to control advanced cancer. Thus, the development of combination strategies involving radiation, chemotherapy, and androgen manipulation as well as immune checkpoint blockade is critical to achieve clinical success. Testing a variety of combination approaches is impractical in the clinic but is achievable using a targeted model approach involving transgenic animals that spontaneously develop prostate cancer. The full genetic characterization of the specific T cells rendered unresponsive by cancer forms the scientific basis for this approach, and has the potential to define new molecular targets and pathways to augment vaccine efficacy. Finally, characterization of patients'' immune response to prostate cancer in the presence or absence of vaccination will determine new cellular targets for vaccination. In summary, the Drake laboratory has undertaken an interactive approach in which discoveries in the laboratory guide clinical trial development, and the results of these trials will feed back to the laboratory to further refine and expand the role of immunotherapy approaches for patients with prostate cancer.
Journal Citations
Litvinov, I.V.; Vander Griend, D.J.; Antony, L.; Dalrymple, S.; De Marzo, A.M.; Drake, C.G.; Isaacs, J.T. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-15090.
Palapattu, G.S.; Meeker, A.; Harris, T.; Collector, M.I.; Sharkis, S.J.; DeMarzo, A.M.; Warlick, C.; Drake, C.G.; Nelson, W.G. Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium. J Urol. 2006 Aug;176(2):813-818.
Zhou, G.; Drake, C.G.; Levitsky, H.I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006 Jan 15;107(2):628-636.
De Marzo, A.M.; Platz, E.A.; Sutcliffe, S.; Xu, J.; Gronberg, H.; Drake, C.G.; Nakai, Y.; Isaacs, W.B.; Nelson, W.G. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007 Apr;7(4):256-269.
Goldberg, M.V.; Maris, C.H.; Hipkiss, E.L.; Flies, A.S.; Zhen, L.; Tuder, R.M.; Grosso, J.F.; Harris, T.J.; Getnet, D.; Whartenby, K.A.; Brockstedt, D.G.; Dubensky, T.W., Jr.; Chen, L.; Pardoll, D.M.; Drake, C.G. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007 Jul 1;110(1):186-192.
Grosso, J.F.; Drake, C.G. Current immunotherapeutic strategies in prostate cancer. Surgical oncology clinics of North America. 2007 Oct;16(4):861-871, x.
Grosso, J.F.; Kelleher, C.C.; Harris, T.J.; Maris, C.H.; Hipkiss, E.L.; De Marzo, A.; Anders, R.; Netto, G.; Getnet, D.; Bruno, T.C.; Goldberg, M.V.; Pardoll, D.M.; Drake, C.G. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007 Nov;117(11):3383-3392.
Harris, T.J.; Grosso, J.F.; Yen, H.R.; Xin, H.; Kortylewski, M.; Albesiano, E.; Hipkiss, E.L.; Getnet, D.; Goldberg, M.V.; Maris, C.H.; Housseau, F.; Yu, H.; Pardoll, D.M.; Drake, C.G. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol. 2007 Oct 1;179(7):4313-4317.
Keller, E.T.; Rowley, D.R.; Tomlins, S.A.; Drake, C.G.; Kantoff, P.W.; Pienta, K.J.; Montie, J.E.; Carter, H.B.; Hruszkewicz, A.M.; Gomez, J.; Mohla, S.; Getzenberg, R.H. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res. 2007 Oct 15;67(20):9613-9615.
Drake, C.G. Immunotherapy for metastatic prostate cancer. Urol Oncol. 2008 Jul-Aug;26(4):438-444.
Harris, T.J.; Hipkiss, E.L.; Borzillary, S.; Wada, S.; Grosso, J.F.; Yen, H.R.; Getnet, D.; Bruno, T.C.; Goldberg, M.V.; Pardoll, D.M.; DeWeese, T.L.; Drake, C.G. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate. 2008 Sep 1;68(12):1319-1329.
Sfanos, K.S.; Bruno, T.C.; Maris, C.H.; Xu, L.; Thoburn, C.J.; DeMarzo, A.M.; Meeker, A.K.; Isaacs, W.B.; Drake, C.G. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008 Jun 1;14(11):3254-3261.
Zarek, P.E.; Huang, C.T.; Lutz, E.R.; Kowalski, J.; Horton, M.R.; Linden, J.; Drake, C.G.; Powell, J.D. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008 Jan 1;111(1):251-259.
An, S.S.; Kim, J.; Ahn, K.; Trepat, X.; Drake, K.J.; Kumar, S.; Ling, G.; Purington, C.; Rangasamy, T.; Kensler, T.W.; Mitzner, W.; Fredberg, J.J.; Biswal, S. Cell stiffness, contractile stress and the role of extracellular matrix. Biochem Biophys Res Commun. 2009 May 15;382(4):697-703.
Drake, C.G. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol. 2009 Sep 1;27(25):4035-4037.
Getnet, D.; Maris, C.H.; Hipkiss, E.L.; Grosso, J.F.; Harris, T.J.; Yen, H.R.; Bruno, T.C.; Wada, S.; Adler, A.; Georgantas, R.W.; Jie, C.; Goldberg, M.V.; Pardoll, D.M.; Drake, C.G. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol. 2009 Apr 15;182(8):4675-4685.
Grosso, J.F.; Goldberg, M.V.; Getnet, D.; Bruno, T.C.; Yen, H.R.; Pyle, K.J.; Hipkiss, E.; Vignali, D.A.; Pardoll, D.M.; Drake, C.G. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 2009 Jun 1;182(11):6659-6669.
Kortylewski, M.; Xin, H.; Kujawski, M.; Lee, H.; Liu, Y.; Harris, T.; Drake, C.; Pardoll, D.; Yu, H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009 Feb 3;15(2):114-123.
Levy, M.Y.; Sidana, A.; Chowdhury, W.H.; Solomon, S.B.; Drake, C.G.; Rodriguez, R.; Fuchs, E.J. Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther. 2009 Aug;330(2):596-601.
Pan, F.; Yu, H.; Dang, E.V.; Barbi, J.; Pan, X.; Grosso, J.F.; Jinasena, D.; Sharma, S.M.; McCadden, E.M.; Getnet, D.; Drake, C.G.; Liu, J.O.; Ostrowski, M.C.; Pardoll, D.M. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science. 2009 Aug 28;325(5944):1142-1146.
Sfanos, K.S.; Bruno, T.C.; Meeker, A.K.; De Marzo, A.M.; Isaacs, W.B.; Drake, C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate. 2009 Nov 1;69(15):1694-1703.
Wada, S.; Yoshimura, K.; Hipkiss, E.L.; Harris, T.J.; Yen, H.R.; Goldberg, M.V.; Grosso, J.F.; Getnet, D.; Demarzo, A.M.; Netto, G.J.; Anders, R.; Pardoll, D.M.; Drake, C.G. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009 May 15;69(10):4309-4318.
Wang, M.H.; Helzlsouer, K.J.; Smith, M.W.; Hoffman-Bolton, J.A.; Clipp, S.L.; Grinberg, V.; De Marzo, A.M.; Isaacs, W.B.; Drake, C.G.; Shugart, Y.Y.; Platz, E.A. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate. 2009 Jun 1;69(8):874-885.
Workman, C.J.; Wang, Y.; El Kasmi, K.C.; Pardoll, D.M.; Murray, P.J.; Drake, C.G.; Vignali, D.A. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009 Feb 15;182(4):1885-1891.
Yen, H.R.; Harris, T.J.; Wada, S.; Grosso, J.F.; Getnet, D.; Goldberg, M.V.; Liang, K.L.; Bruno, T.C.; Pyle, K.J.; Chan, S.L.; Anders, R.A.; Trimble, C.L.; Adler, A.J.; Lin, T.Y.; Pardoll, D.M.; Huang, C.T.; Drake, C.G. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol. 2009 Dec 1;183(11):7161-7168.
Antonarakis, E.S.; Drake, C.G. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010 May;20(3):241-246.
Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-3175.
Drake, C. Consultation corner. Prostate cancer vaccine offers new direction. Johns Hopkins Med Lett Health After 50. 2010 Sep;22(7):6-7.
Drake, C.G. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010 Aug;10(8):580-593.
Drake, C.G. Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am. 2010 Feb;37(1):121-129, Table of Contents.
Drake, C.G.; Antonarakis, E.S. Update: immunological strategies for prostate cancer. Curr Urol Rep. 2010 May;11(3):202-207.
Getnet, D.; Grosso, J.F.; Goldberg, M.V.; Harris, T.J.; Yen, H.R.; Bruno, T.C.; Durham, N.M.; Hipkiss, E.L.; Pyle, K.J.; Wada, S.; Pan, F.; Pardoll, D.M.; Drake, C.G. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol. 2010 Apr;47(7-8):1595-1600.
Goldberg, M.V.; Drake, C.G. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol. 2010 Nov 18;Epub 11/19/10.
Hales, R.K.; Banchereau, J.; Ribas, A.; Tarhini, A.A.; Weber, J.S.; Fox, B.A.; Drake, C.G. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol. 2010 Oct;21(10):1944-1951.
Hsu, D.S.; Kim, M.K.; Balakumaran, B.S.; Acharya, C.R.; Anders, C.K.; Clay, T.; Lyerly, H.K.; Drake, C.G.; Morse, M.A.; Febbo, P.G. Immune signatures predict prognosis in localized cancer. Cancer Invest. 2010 Aug;28(7):765-773.
Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
Platz, E.A.; Sutcliffe, S.; De Marzo, A.M.; Drake, C.G.; Rifai, N.; Hsing, A.W.; Hoque, A.; Neuhouser, M.L.; Goodman, P.J.; Kristal, A.R. Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. Cancer Causes Control. 2010 Jun;21(6):847-851.
Radojcic, V.; Pletneva, M.A.; Yen, H.R.; Ivcevic, S.; Panoskaltsis-Mortari, A.; Gilliam, A.C.; Drake, C.G.; Blazar, B.R.; Luznik, L. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010 Jan 15;184(2):764-774.
Woo, S.R.; Li, N.; Bruno, T.C.; Forbes, K.; Brown, S.; Workman, C.; Drake, C.G.; Vignali, D.A. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol. 2010 Jun;40(6):1768-1777.
To date, clinical trials of immunotherapy in patients with solid tumors have been somewhat disappointing, with response rates less than would be predicted by standard transplantable models. It seems increasingly unlikely that immunotherapy alone will prove sufficient to control advanced cancer. Thus, the development of combination strategies involving radiation, chemotherapy, and androgen manipulation as well as immune checkpoint blockade is critical to achieve clinical success. Testing a variety of combination approaches is impractical in the clinic but is achievable using a targeted model approach involving transgenic animals that spontaneously develop prostate cancer. The full genetic characterization of the specific T cells rendered unresponsive by cancer forms the scientific basis for this approach, and has the potential to define new molecular targets and pathways to augment vaccine efficacy. Finally, characterization of patients'' immune response to prostate cancer in the presence or absence of vaccination will determine new cellular targets for vaccination. In summary, the Drake laboratory has undertaken an interactive approach in which discoveries in the laboratory guide clinical trial development, and the results of these trials will feed back to the laboratory to further refine and expand the role of immunotherapy approaches for patients with prostate cancer.
Journal Citations
Litvinov, I.V.; Vander Griend, D.J.; Antony, L.; Dalrymple, S.; De Marzo, A.M.; Drake, C.G.; Isaacs, J.T. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-15090.
Palapattu, G.S.; Meeker, A.; Harris, T.; Collector, M.I.; Sharkis, S.J.; DeMarzo, A.M.; Warlick, C.; Drake, C.G.; Nelson, W.G. Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium. J Urol. 2006 Aug;176(2):813-818.
Zhou, G.; Drake, C.G.; Levitsky, H.I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006 Jan 15;107(2):628-636.
De Marzo, A.M.; Platz, E.A.; Sutcliffe, S.; Xu, J.; Gronberg, H.; Drake, C.G.; Nakai, Y.; Isaacs, W.B.; Nelson, W.G. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007 Apr;7(4):256-269.
Goldberg, M.V.; Maris, C.H.; Hipkiss, E.L.; Flies, A.S.; Zhen, L.; Tuder, R.M.; Grosso, J.F.; Harris, T.J.; Getnet, D.; Whartenby, K.A.; Brockstedt, D.G.; Dubensky, T.W., Jr.; Chen, L.; Pardoll, D.M.; Drake, C.G. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007 Jul 1;110(1):186-192.
Grosso, J.F.; Drake, C.G. Current immunotherapeutic strategies in prostate cancer. Surgical oncology clinics of North America. 2007 Oct;16(4):861-871, x.
Grosso, J.F.; Kelleher, C.C.; Harris, T.J.; Maris, C.H.; Hipkiss, E.L.; De Marzo, A.; Anders, R.; Netto, G.; Getnet, D.; Bruno, T.C.; Goldberg, M.V.; Pardoll, D.M.; Drake, C.G. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007 Nov;117(11):3383-3392.
Harris, T.J.; Grosso, J.F.; Yen, H.R.; Xin, H.; Kortylewski, M.; Albesiano, E.; Hipkiss, E.L.; Getnet, D.; Goldberg, M.V.; Maris, C.H.; Housseau, F.; Yu, H.; Pardoll, D.M.; Drake, C.G. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol. 2007 Oct 1;179(7):4313-4317.
Keller, E.T.; Rowley, D.R.; Tomlins, S.A.; Drake, C.G.; Kantoff, P.W.; Pienta, K.J.; Montie, J.E.; Carter, H.B.; Hruszkewicz, A.M.; Gomez, J.; Mohla, S.; Getzenberg, R.H. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res. 2007 Oct 15;67(20):9613-9615.
Drake, C.G. Immunotherapy for metastatic prostate cancer. Urol Oncol. 2008 Jul-Aug;26(4):438-444.
Harris, T.J.; Hipkiss, E.L.; Borzillary, S.; Wada, S.; Grosso, J.F.; Yen, H.R.; Getnet, D.; Bruno, T.C.; Goldberg, M.V.; Pardoll, D.M.; DeWeese, T.L.; Drake, C.G. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate. 2008 Sep 1;68(12):1319-1329.
Sfanos, K.S.; Bruno, T.C.; Maris, C.H.; Xu, L.; Thoburn, C.J.; DeMarzo, A.M.; Meeker, A.K.; Isaacs, W.B.; Drake, C.G. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008 Jun 1;14(11):3254-3261.
Zarek, P.E.; Huang, C.T.; Lutz, E.R.; Kowalski, J.; Horton, M.R.; Linden, J.; Drake, C.G.; Powell, J.D. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008 Jan 1;111(1):251-259.
An, S.S.; Kim, J.; Ahn, K.; Trepat, X.; Drake, K.J.; Kumar, S.; Ling, G.; Purington, C.; Rangasamy, T.; Kensler, T.W.; Mitzner, W.; Fredberg, J.J.; Biswal, S. Cell stiffness, contractile stress and the role of extracellular matrix. Biochem Biophys Res Commun. 2009 May 15;382(4):697-703.
Drake, C.G. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol. 2009 Sep 1;27(25):4035-4037.
Getnet, D.; Maris, C.H.; Hipkiss, E.L.; Grosso, J.F.; Harris, T.J.; Yen, H.R.; Bruno, T.C.; Wada, S.; Adler, A.; Georgantas, R.W.; Jie, C.; Goldberg, M.V.; Pardoll, D.M.; Drake, C.G. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol. 2009 Apr 15;182(8):4675-4685.
Grosso, J.F.; Goldberg, M.V.; Getnet, D.; Bruno, T.C.; Yen, H.R.; Pyle, K.J.; Hipkiss, E.; Vignali, D.A.; Pardoll, D.M.; Drake, C.G. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 2009 Jun 1;182(11):6659-6669.
Kortylewski, M.; Xin, H.; Kujawski, M.; Lee, H.; Liu, Y.; Harris, T.; Drake, C.; Pardoll, D.; Yu, H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009 Feb 3;15(2):114-123.
Levy, M.Y.; Sidana, A.; Chowdhury, W.H.; Solomon, S.B.; Drake, C.G.; Rodriguez, R.; Fuchs, E.J. Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther. 2009 Aug;330(2):596-601.
Pan, F.; Yu, H.; Dang, E.V.; Barbi, J.; Pan, X.; Grosso, J.F.; Jinasena, D.; Sharma, S.M.; McCadden, E.M.; Getnet, D.; Drake, C.G.; Liu, J.O.; Ostrowski, M.C.; Pardoll, D.M. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science. 2009 Aug 28;325(5944):1142-1146.
Sfanos, K.S.; Bruno, T.C.; Meeker, A.K.; De Marzo, A.M.; Isaacs, W.B.; Drake, C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate. 2009 Nov 1;69(15):1694-1703.
Wada, S.; Yoshimura, K.; Hipkiss, E.L.; Harris, T.J.; Yen, H.R.; Goldberg, M.V.; Grosso, J.F.; Getnet, D.; Demarzo, A.M.; Netto, G.J.; Anders, R.; Pardoll, D.M.; Drake, C.G. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009 May 15;69(10):4309-4318.
Wang, M.H.; Helzlsouer, K.J.; Smith, M.W.; Hoffman-Bolton, J.A.; Clipp, S.L.; Grinberg, V.; De Marzo, A.M.; Isaacs, W.B.; Drake, C.G.; Shugart, Y.Y.; Platz, E.A. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate. 2009 Jun 1;69(8):874-885.
Workman, C.J.; Wang, Y.; El Kasmi, K.C.; Pardoll, D.M.; Murray, P.J.; Drake, C.G.; Vignali, D.A. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009 Feb 15;182(4):1885-1891.
Yen, H.R.; Harris, T.J.; Wada, S.; Grosso, J.F.; Getnet, D.; Goldberg, M.V.; Liang, K.L.; Bruno, T.C.; Pyle, K.J.; Chan, S.L.; Anders, R.A.; Trimble, C.L.; Adler, A.J.; Lin, T.Y.; Pardoll, D.M.; Huang, C.T.; Drake, C.G. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol. 2009 Dec 1;183(11):7161-7168.
Antonarakis, E.S.; Drake, C.G. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010 May;20(3):241-246.
Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-3175.
Drake, C. Consultation corner. Prostate cancer vaccine offers new direction. Johns Hopkins Med Lett Health After 50. 2010 Sep;22(7):6-7.
Drake, C.G. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010 Aug;10(8):580-593.
Drake, C.G. Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am. 2010 Feb;37(1):121-129, Table of Contents.
Drake, C.G.; Antonarakis, E.S. Update: immunological strategies for prostate cancer. Curr Urol Rep. 2010 May;11(3):202-207.
Getnet, D.; Grosso, J.F.; Goldberg, M.V.; Harris, T.J.; Yen, H.R.; Bruno, T.C.; Durham, N.M.; Hipkiss, E.L.; Pyle, K.J.; Wada, S.; Pan, F.; Pardoll, D.M.; Drake, C.G. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol. 2010 Apr;47(7-8):1595-1600.
Goldberg, M.V.; Drake, C.G. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol. 2010 Nov 18;Epub 11/19/10.
Hales, R.K.; Banchereau, J.; Ribas, A.; Tarhini, A.A.; Weber, J.S.; Fox, B.A.; Drake, C.G. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol. 2010 Oct;21(10):1944-1951.
Hsu, D.S.; Kim, M.K.; Balakumaran, B.S.; Acharya, C.R.; Anders, C.K.; Clay, T.; Lyerly, H.K.; Drake, C.G.; Morse, M.A.; Febbo, P.G. Immune signatures predict prognosis in localized cancer. Cancer Invest. 2010 Aug;28(7):765-773.
Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
Platz, E.A.; Sutcliffe, S.; De Marzo, A.M.; Drake, C.G.; Rifai, N.; Hsing, A.W.; Hoque, A.; Neuhouser, M.L.; Goodman, P.J.; Kristal, A.R. Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. Cancer Causes Control. 2010 Jun;21(6):847-851.
Radojcic, V.; Pletneva, M.A.; Yen, H.R.; Ivcevic, S.; Panoskaltsis-Mortari, A.; Gilliam, A.C.; Drake, C.G.; Blazar, B.R.; Luznik, L. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010 Jan 15;184(2):764-774.
Woo, S.R.; Li, N.; Bruno, T.C.; Forbes, K.; Brown, S.; Workman, C.; Drake, C.G.; Vignali, D.A. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol. 2010 Jun;40(6):1768-1777.
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts